CRISPR Therapeutics informa las ganancias trimestralmente. Estos informes de ganancias trimestrales ofrecen a los inversores una visión de los resultados financieros de una empresa durante un período de 3 meses. Los informes de ganancias casi siempre incluyen resultados de EPS e ingresos.
Analice el historial de beneficios de CRISPR Therapeutics utilizando filtros y clasificaciones avanzadas.
Get Alert | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
CRSP | CRISPR Therapeutics | -$1.01 | -$1.31 | — | — | $602.00K | $12.58M | — | — | 11/04/2025 | |
CRSP | CRISPR Therapeutics | -$1.49 | -$1.47 | -$1.29 | 9.79% | $517.00K | $6.25M | $892.00K | -86.27% | 08/04/2025 | |
CRSP | CRISPR Therapeutics | -$1.43 | -$1.30 | -$1.58 | -26.40% | $504.00K | $8.98M | $865.00K | -86.46% | 05/06/2025 | |
CRSP | CRISPR Therapeutics | $1.10 | -$1.35 | -$0.44 | 63.64% | $201.21M | $10.50M | $35.69M | 383.62% | 02/11/2025 | |
CRSP | CRISPR Therapeutics | -$1.41 | -$1.42 | -$1.01 | 28.87% | $0.00 | $6.81M | $602.00K | -91.16% | 11/05/2024 | |
CRSP | CRISPR Therapeutics | -$0.98 | -$1.40 | -$1.49 | 1.97% | $70.00M | $16.57M | $517.00K | -85.40% | 08/05/2024 | |
CRSP | CRISPR Therapeutics | -$0.67 | -$1.42 | -$1.43 | -0.70% | $100.00M | $28.11M | $504.00K | -98.21% | 05/08/2024 | |
CRSP | CRISPR Therapeutics | -$1.41 | -$0.07 | $1.10 | 1671.43% | $6.00K | $131.63M | $201.21M | 52.86% | 02/21/2024 | |
CRSP | CRISPR Therapeutics | -$2.24 | -$1.96 | -$1.41 | 28.06% | $94.00K | $8.43M | $0.00 | -100.00% | 11/06/2023 | |
CRSP | CRISPR Therapeutics | -$2.40 | -$2.12 | -$0.98 | 53.77% | $158.00K | $1.71M | $70.00M | 3993.57% | 08/07/2023 | |
CRSP | CRISPR Therapeutics | -$2.32 | -$1.70 | -$0.67 | 60.59% | $940.00K | $22.98M | $100.00M | 335.16% | 05/08/2023 | |
CRSP | CRISPR Therapeutics | -$1.84 | -$2.30 | -$1.41 | 38.70% | $12.90M | $7.12M | $6.00K | -99.92% | 02/21/2023 | |
CRSP | CRISPR Therapeutics | -$1.67 | -$2.29 | -$2.24 | 2.18% | $824.00K | $1.62M | $94.00K | -94.20% | 11/01/2022 | |
CRSP | CRISPR Therapeutics | $9.44 | -$2.23 | -$2.40 | -7.62% | $900.70M | $2.06M | $158.00K | -92.33% | 08/08/2022 | |
CRSP | CRISPR Therapeutics | -$1.51 | — | -$2.32 | — | $539.00K | — | $940.00K | — | 05/09/2022 | |
CRSP | CRISPR Therapeutics | -$1.50 | -$1.77 | -$1.84 | -3.95% | $370.00K | $2.27M | $12.90M | 468.24% | 02/15/2022 | |
CRSP | CRISPR Therapeutics | -$1.32 | -$1.76 | -$1.67 | 5.11% | $148.00K | $1.12M | $824.00K | -26.43% | 11/03/2021 | |
CRSP | CRISPR Therapeutics | -$1.30 | $3.52 | $9.44 | 168.18% | $44.00K | $420.92M | $900.70M | 113.98% | 07/29/2021 | |
CRSP | CRISPR Therapeutics | -$1.15 | -$1.47 | -$1.51 | -2.72% | $157.00K | $1.14M | $539.00K | — | 04/27/2021 | |
CRSP | CRISPR Therapeutics | $0.51 | -$1.27 | -$1.50 | -18.11% | $77.02M | $2.32M | $370.00K | -84.05% | 02/16/2021 | |
CRSP | CRISPR Therapeutics | $2.40 | -$1.18 | -$1.32 | -11.86% | $211.93M | $2.06M | $148.00K | -92.82% | 10/28/2020 |
Trimestre Fiscal | Fecha reportada | EPS real | EPS estimado | Sorpresa % |
---|---|---|---|---|
Q2 | 2025-08-04 | $-1.29 | $-1.47 | 9.79 % |
Q1 | 2025-05-06 | $-1.58 | $-1.30 | -26.4 % |
Q4 | 2025-02-11 | $-0.44 | $-1.35 | 63.6 % |
Q3 | 2024-11-05 | $-1.01 | $-1.42 | 28.9 % |
Trimestre Fiscal | Fecha reportada | Ingresos reales | Ingresos estimados | Sorpresa % |
---|---|---|---|---|
Q2 | 2025-08-04 | $892.00K | $6.25M | -86.3 % |
Q1 | 2025-05-06 | $865.00K | $8.98M | -86.5 % |
Q4 | 2025-02-11 | $35.69M | $10.50M | 383.6 % |
Q3 | 2024-11-05 | $602.00K | $6.81M | -91.2 % |
Está previsto que CRISPR Therapeutics (CRSP) presente resultados el noviembre 4, 2025. Los últimos resultados se publicaron el agosto 4, 2025 para el Q2.
El BPA real fue de $-1.29, que superó la estimación de $-1.46.
Los ingresos reales fueron $892K, que no alcanzó la estimación de $6.3M.
Explora Estimaciones de beneficios, BPA e ingresos sobre todos los valores.